Company news
InventisBio, Co., Ltd. news in 2026
InventisBio, Co., Ltd.'s news releases, calls and decks from 2026, newest first.
(688382)"INVENTISBIO CO., LIMITED"Announcement on the Phase III Clinical Study of Nomelcitinib (D-2570) for the Treatment of Moderate-to-Severe Plaque Psoriasis Achieving the Primary Endpoint
November 1, 2026
(688382)"INVENTISBIO CO., LIMITED"Report for Q3 2026
October 29, 2026
(688382)"INVENTISBIO CO., LIMITED"Announcement on Vesting Results for the Third Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan and Listing of Shares
October 27, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 25, 2026
Announcement on the Satisfaction of Vesting Conditions for the 3rd Vesting Period of the Reserved Grant under the 2022 Restricted Share Incentive Plan
August 21, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 20, 2026
Announcement on Signing Quadripartite Supervision Agreement for Deposit of Raised Funds in Special Account
July 22, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2026
Announcement on Adding Implementing Entities for Some Investment Projects Financed by Raised Funds and Opening Special Fundraising Accounts
July 2, 2026
Announcement on Granting Restricted Stocks to Incentive Objects of 2026 Restricted Stock Incentive Plan
June 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 18, 2026
Publicity Explanation and Verification Opinions of Remuneration and Appraisal Committee of Board of Directors on List of Incentive Objects in 2026 Restricted Stock Incentive Plan
June 11, 2026
Announcement on Vesting Results of the 3rd Vesting Period of Those Initially Granted and the 2nd Vesting Period of Those Reserved for Grant (2nd Batch) in 2022 Restricted Stock Incentive Plan and Listing of Shares
June 1, 2026
Announcement on Resolutions of the 6th Meeting of the 2nd Board of Directors in 2026
May 28, 2026
Report for Q1 2026
April 28, 2026
Announcement on Achievements of Vesting Conditions in the 3rd Vesting Period of Those Initially Granted (2nd Batch) and the 2nd Vesting Period of Those Reserved for Grant in 2022 Restricted Stock Incentive Plan
April 14, 2026
Announcement on Convening the 2025 Annual Performance Briefing
April 9, 2026
Announcement on Termination of the 2025 Restricted Stock Incentive Plan
March 27, 2026
Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis
March 26, 2026
Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States
March 18, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 26, 2026
Announcement on Cancellation of Some Proposals at the 1st Extraordinary General Meeting in 2026
February 13, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
February 10, 2026
Announcement on Expected Loss in Performance for 2025
January 29, 2026
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
January 16, 2026
Publicity Explanation and Verification Opinions of Remuneration and Appraisal Committee of Board of Directors on List of Incentive Objects in 2025 Restricted Stock Incentive Plan
January 7, 2026